Skip to main content
SpringerLink
Log in

Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this retrospective study was to evaluate the prognostic role of gross tumor volume (GTV) on survival of locally advanced NSCLC patients, regardless of TNM stage, and to analyze whether GTV and other radiotherapy (RT) parameters wre important for the development of lung toxicity. Thirty-two patients with locally advanced NSCLC (stage IIIA bulky/IIIB) treated with chemoradiotherapy were retrospectively analyzed. Patients received induction chemotherapy followed by combination treatment (27 patients) or induction chemotherapy followed by RT alone (5 patients). Thoracic RT consisted in 60 Gy, with standard fractionation and was the same for all 32 patients. Dose volume histograms were collected from the 3D treatment plans and GTV, planning target volume, mean lung dose, volume of lung receiving more than 20 Gy or more than 30 Gy were analyzed. Survival was significantly longer in patients with a GTV<100 cm3 compared with patients having GTV>100 cm3 (p=0.03). In a multivariate analysis only N-status and GTV were predictors of survival with a risk ratio of 0.51 and 0.62, respectively. Ten patients (31%) developed radiation pneumonitis grade 2 or higher. None of the RT parameters examined correlated significantly with the development of lung toxicity. In locally advanced NSCLC, GTV and N-status play a prognostic role even in patients at the same clinical stage and receiving a combination of chemo- and radiotherapy. This could imply a reassessment of the current staging system in patients with non-resectable NSCLC to better identify those patients who would benefit more from the combined treatment, despite its higher toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Martel MK, et al. Volume and dose parameters for survival of nonsmall cell lung cancer patients. Radiother Oncol 1997;44:23–29.

    Article  PubMed  CAS  Google Scholar 

  2. Bradley JD, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002;52:49–57.

    Article  PubMed  Google Scholar 

  3. Etiz D, et al. Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;53:835–846.

    Article  PubMed  Google Scholar 

  4. Kwa SL, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998;42:1–9.

    Article  PubMed  CAS  Google Scholar 

  5. Hernando ML, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001;51:650–659.

    Article  PubMed  CAS  Google Scholar 

  6. Isokangas OP, Joensuu H, Halme M, Jekunen A, and Mattson K. Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC. Lung Cancer 1998;20:127–133.

    Article  PubMed  CAS  Google Scholar 

  7. Willner J, et al. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study. Lung Cancer 2001;32:163–171.

    Article  PubMed  CAS  Google Scholar 

  8. Willner J, Jost A, Baier K, Flentje M. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 2003;179:548–556.

    Article  PubMed  Google Scholar 

  9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457–481.

    Article  Google Scholar 

  10. Cox DR. Regression models and life tables. J R Statist Soc 1966;34:187–220.

    Google Scholar 

  11. Pfister DG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330–353.

    Article  PubMed  Google Scholar 

  12. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:382–389.

    Article  PubMed  Google Scholar 

  13. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001;51:56–61.

    Article  PubMed  CAS  Google Scholar 

  14. Robnett TJ, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48:89–94.

    Article  PubMed  CAS  Google Scholar 

  15. Inoue A, et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001;49: 649–655.

    Article  PubMed  CAS  Google Scholar 

  16. Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998;34:71–75.

    Article  PubMed  CAS  Google Scholar 

  17. Segawa Y, et al. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1997;39:91–98.

    Article  PubMed  CAS  Google Scholar 

  18. Tsujino K, et al. Predictive value of dose-volume histogram parmeters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2003;55:110–115.

    Article  PubMed  Google Scholar 

  19. Oetzel D, et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 1995;33:455–460.

    Article  PubMed  CAS  Google Scholar 

  20. Yorke ED, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:329–339.

    Article  PubMed  Google Scholar 

  21. Martel MK, et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int. J Radiat Oncol Biol Phys 1994;28:575–581.

    PubMed  CAS  Google Scholar 

  22. Graham MV, et al. Clinical dose-volume histogram analysis for penumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323–329.

    Article  PubMed  CAS  Google Scholar 

  23. Jenkins P, D’Amico K, Benstead K, Elyan S. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 2003;56:360–366.

    Article  PubMed  Google Scholar 

  24. Marks LB, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 1997;39:563–570.

    Article  PubMed  CAS  Google Scholar 

  25. Byhardt RW, et al. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)—analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 1993;27:537–544.

    PubMed  CAS  Google Scholar 

  26. Seppenwoolde Y, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003;55:724–735.

    Article  PubMed  Google Scholar 

  27. Roach M, 3rd, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995;13:2606–2612.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hospital Physics, Karolinska University Hospital, 17176, Stockholm, Sweden

    Ingmar Lax

  2. Dpt. of Oncology and Pathology, Radiumhemmet, Karolinska University Hospital, 17176, Stockholm, Sweden

    Luigi De Petris, Florin Sirzén & Signe Friesland MD, PhD

Authors
  1. Luigi De Petris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingmar Lax
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florin Sirzén
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Signe Friesland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Signe Friesland MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Petris, L., Lax, I., Sirzén, F. et al. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol 22, 375–381 (2005). https://doi.org/10.1385/MO:22:4:375

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:22:4:375

Key Words

Search

Navigation